Ongen Zeki, Yilmaz Yeşim, Karadağ Bilgehan
Department of Cardiology, Cerrahpaşa Medical Faculty of Istanbul University, Istanbul, Turkey.
Turk Kardiyol Dern Ars. 2009 Mar;37 Suppl 2:23-8.
During the 10 years of atorvastatin availability in the Turkish market, the physicians have had the opportunity to observe the accumulation of data related to its beneficial effect on clinical endpoints. The scope of this review is limited to the trials concerning the role of atorvastatin in secondary prevention. In GREACE and ALLIANCE studies, the benefit of atorvastatin was demonstrated in patients with coronary heart disease in real-world setting. TNT was the first trial which showed that aggressive lipid lowering therapy was more protective than a moderate one in patients with stable coronary artery disease. In the MIRACL trial, 80 mg atorvastatin was compared with placebo and found effective in preventing ischemic events in patients with non-ST elevation acute coronary syndromes. PROVE-IT proved that aggressive lipid lowering therapy with atorvastatin 80 mg was much more effective than moderate therapy (pravastatin 40 mg) in patients with all types of acute coronary syndromes. AVERT was the first statin trial to show that aggressive therapy with atorvastatin was at least as effective as angioplasty in patients with stable coronary artery disease. The SPARCL trial demonstrated the efficacy of atorvastatin in secondary prevention of patients with stroke.
在阿托伐他汀于土耳其市场上市的10年期间，医生们有机会观察到与其对临床终点有益作用相关的数据积累。本综述的范围仅限于有关阿托伐他汀在二级预防中作用的试验。在GREACE和ALLIANCE研究中，阿托伐他汀在现实环境中的冠心病患者中显示出益处。TNT是首个表明积极降脂治疗比适度降脂治疗对稳定型冠状动脉疾病患者更具保护作用的试验。在MIRACL试验中，将80毫克阿托伐他汀与安慰剂进行比较，发现其对非ST段抬高急性冠状动脉综合征患者预防缺血事件有效。PROVE-IT证明，在所有类型的急性冠状动脉综合征患者中，使用80毫克阿托伐他汀进行积极降脂治疗比适度治疗（40毫克普伐他汀）有效得多。AVERT是首个表明阿托伐他汀积极治疗在稳定型冠状动脉疾病患者中至少与血管成形术一样有效的他汀类药物试验。SPARCL试验证明了阿托伐他汀在中风患者二级预防中的疗效。
